Cargando…
Acute Myeloid Leukemia: A Concise Review
Acute myeloid leukemia (AML) is a heterogeneous clonal disorder characterized by immature myeloid cell proliferation and bone marrow failure. Cytogenetics and mutation testing remain a critical prognostic tool for post induction treatment. Despite rapid advances in the field including new drug targe...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810104/ https://www.ncbi.nlm.nih.gov/pubmed/26959069 http://dx.doi.org/10.3390/jcm5030033 |
_version_ | 1782423725551910912 |
---|---|
author | Saultz, Jennifer N. Garzon, Ramiro |
author_facet | Saultz, Jennifer N. Garzon, Ramiro |
author_sort | Saultz, Jennifer N. |
collection | PubMed |
description | Acute myeloid leukemia (AML) is a heterogeneous clonal disorder characterized by immature myeloid cell proliferation and bone marrow failure. Cytogenetics and mutation testing remain a critical prognostic tool for post induction treatment. Despite rapid advances in the field including new drug targets and increased understanding of the biology, AML treatment remains unchanged for the past three decades with the majority of patients eventually relapsing and dying of the disease. Allogenic transplant remains the best chance for cure for patients with intermediate or high risk disease. In this review, we discuss the landmark genetic studies that have improved outcome prediction and novel therapies. |
format | Online Article Text |
id | pubmed-4810104 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-48101042016-04-04 Acute Myeloid Leukemia: A Concise Review Saultz, Jennifer N. Garzon, Ramiro J Clin Med Review Acute myeloid leukemia (AML) is a heterogeneous clonal disorder characterized by immature myeloid cell proliferation and bone marrow failure. Cytogenetics and mutation testing remain a critical prognostic tool for post induction treatment. Despite rapid advances in the field including new drug targets and increased understanding of the biology, AML treatment remains unchanged for the past three decades with the majority of patients eventually relapsing and dying of the disease. Allogenic transplant remains the best chance for cure for patients with intermediate or high risk disease. In this review, we discuss the landmark genetic studies that have improved outcome prediction and novel therapies. MDPI 2016-03-05 /pmc/articles/PMC4810104/ /pubmed/26959069 http://dx.doi.org/10.3390/jcm5030033 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Saultz, Jennifer N. Garzon, Ramiro Acute Myeloid Leukemia: A Concise Review |
title | Acute Myeloid Leukemia: A Concise Review |
title_full | Acute Myeloid Leukemia: A Concise Review |
title_fullStr | Acute Myeloid Leukemia: A Concise Review |
title_full_unstemmed | Acute Myeloid Leukemia: A Concise Review |
title_short | Acute Myeloid Leukemia: A Concise Review |
title_sort | acute myeloid leukemia: a concise review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810104/ https://www.ncbi.nlm.nih.gov/pubmed/26959069 http://dx.doi.org/10.3390/jcm5030033 |
work_keys_str_mv | AT saultzjennifern acutemyeloidleukemiaaconcisereview AT garzonramiro acutemyeloidleukemiaaconcisereview |